Rallybio Pursues Reverse Merger with Avenzo Therapeutics to Advance Autoimmune Pipeline

Rallybio Tries Reverse Merger Again, This Time with Avenzo Therapeutics

Rallybio is attempting a reverse merger with Avenzo Therapeutics, a move that will see the combined entity focus on Avenzo's T-cell engager pipeline for autoimmune diseases. The transaction includes a substantial concurrent financing round. The deal rebrands the combined company as Candid Therapeutics and secures over $505 million in committed capital, offering a lifeline for Rallybio after years of clinical setbacks and declining market confidence since its 2021 IPO. Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Key Takeaways

• Rallybio has entered a definitive agreement to acquire Avenzo Therapeutics via reverse merger, with the combined entity operating as Candid Therapeutics and trading on Nasdaq under ticker CDRX.
• A concurrent oversubscribed private financing of over $505 million — led by Venrock Healthcare Capital Partners, RA Capital Management, and T. Rowe Price Associates — is expected to fund operations through 2030.
• Pre-transaction Rallybio equity holders will retain just 3.65% of the combined company, reflecting the near-total transfer of value to Avenzo stakeholders and new investors.
• The merger sheds Rallybio's legacy rare disease maternal-fetal medicine assets and positions the combined company around Avenzo's clinical-stage T-cell engager portfolio, headlined by cizutamig for myasthenia gravis and interstitial lung disease.
• The transaction is expected to close in mid-2026, subject to shareholder approvals and SEC regulatory conditions.

What Is Driving Rallybio's Second Merger Attempt?

The Rallybio Avenzo merger marks the Connecticut-based company's second attempt at a strategic transaction to reset its trajectory. Rallybio went public in 2021 with high expectations for its rare disease pipeline, but the company has since been battered by disappointing clinical trial results, workforce reductions, and a collapsing share price. This reverse merger — technically structured as Rallybio acquiring Avenzo, with Avenzo stakeholders ending up with 96.35% ownership — effectively allows Avenzo to go public on Nasdaq via Rallybio's existing listing while jettisoning Rallybio's legacy maternal-fetal medicine programs.

The combined company will operate as Candid Therapeutics, Inc. under the ticker CDRX. The transaction has been unanimously approved by both boards and is expected to close in mid-2026, pending stockholder votes and the effectiveness of an SEC registration statement covering the shares to be issued. Hart-Scott-Rodino antitrust clearance is also required. Rallybio SEC Filings

How Does Avenzo's T-Cell Engager Platform Work?

Avenzo brings a clinical-stage pipeline of T-cell engager therapeutics — bispecific antibodies designed to redirect T cells to target pathogenic B cells — focused on autoimmune diseases. The lead candidate, cizutamig, is a B-cell maturation antigen (BCMA)-targeting TCE. BCMA is expressed on the surface of plasma cells, including the autoreactive plasma cells that drive several autoimmune conditions. By engaging CD3 on T cells and BCMA on plasma cells simultaneously, cizutamig is designed to deplete these pathogenic cells while sparing other immune populations.

Cizutamig is expected to enter Phase 2 studies in two indications: myasthenia gravis, a chronic neuromuscular autoimmune disease characterized by muscle weakness, and interstitial lung disease secondary to rheumatological conditions — a serious complication with limited treatment options. The over $505 million financing is intended to support not only these Phase 2 programs but also the broader TCE pipeline through multiple clinical milestones. ClinicalTrials.gov: BCMA-targeting therapies in myasthenia gravis

Why Is the $505 Million Financing Significant?

The concurrent private financing round was both oversubscribed and upsized, drawing commitments from a heavyweight syndicate of healthcare institutional investors. Participants include Venrock Healthcare Capital Partners, RA Capital Management, Janus Henderson Investors, accounts advised by T. Rowe Price Associates, venBio Partners, Viking Global Investors, Cormorant Asset Management, Foresite Capital, Soleus Capital, TCGX, Vivo Capital, and several additional mutual funds and institutional investors.

The capital infusion is projected to give the combined company sufficient cash to fund operations through 2030. For a clinical-stage biotech, that kind of runway is unusual and effectively de-risks near-term financing concerns. It also signals strong investor conviction in Avenzo's TCE platform and the autoimmune disease opportunity. The cash position at closing will be a critical metric for BD teams and analysts evaluating Candid's ability to execute its clinical strategy without needing to return to the capital markets.

What Are the Strategic Implications for BD Teams and Investors?

For business development teams, the merger creates a potential new partner with a focused autoimmune pipeline, a substantial cash balance, and a leadership structure aligned around TCE therapeutics. Candid's willingness to invest in multiple Phase 2 readouts simultaneously could accelerate partnership discussions, particularly if early clinical data validates the TCE approach in myasthenia gravis or ILD.

For investors, the calculus is more complex. Existing Rallybio shareholders face extreme dilution — just 3.65% ownership in the combined entity. The value proposition hinges entirely on Avenzo's pipeline delivering clinical milestones over the next several years. Analysts will be watching the execution of the merger close, the design and enrollment of Phase 2 trials for cizutamig, and any competitive data readouts from other TCE programs in autoimmune indications.

Who Are Candid's Key Competitors in Autoimmune T-Cell Engagers?

The development of T-cell engagers for autoimmune diseases is an increasingly active field. Multiple companies are advancing bispecific or TCE-based approaches targeting BCMA or other B-cell markers in autoimmune conditions, including myasthenia gravis, lupus, and other rheumatological diseases. The competitive bar is rising as early clinical data from several programs begins to emerge.

Candid's ability to differentiate will depend on cizutamig's clinical profile — efficacy, safety, and dosing convenience — relative to other TCE candidates. The market's reception of this reverse merger will also hinge on whether investors view Avenzo's pipeline as meaningfully de-risked and differentiated compared to peers. A successful Phase 2 readout in either myasthenia gravis or ILD would be the most important near-term catalyst for establishing competitive positioning.

What Milestones Should Investors Watch Next?

The most immediate milestone is the close of the merger, expected in mid-2026, which requires Rallybio and Candid shareholder approvals and SEC registration effectiveness. Once the transaction closes, attention shifts to the initiation of Phase 2 studies for cizutamig in myasthenia gravis and ILD, along with clinical readouts from those trials. Updates on the broader TCE pipeline — including any additional IND-enabling work or expansion into new autoimmune indications — will also be closely monitored.

The successful operational integration of Rallybio and Avenzo will be another critical factor. With Rallybio's legacy assets being shed, the combined company's leadership, R&D infrastructure, and clinical operations will need to align around Avenzo's programs quickly and efficiently. Any delays in trial initiation or operational disruptions could erode investor confidence in the deal's value proposition.

Frequently Asked Questions

Related coverage

• Chinese Pharma Innovators Expand Globally with Innovative Deal Structures